Transcode Therapeutics, Inc. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
TransCode reported updated Phase 1a data for TTX-MC138 (anti-miR-10b) as of September 1, 2026: 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease; three patients remained progression-free at 12 months; disease control extended through six months in 35.7% of patients; no dose-limiting toxicities reported across all doses including 4.8 mg/kg; exploratory biomarker analysis showed treatment-associated antitumor immune activation. The study met its primary safety endpoint.
Why this rating
Early-stage oncology data with durable clinical signals in heavily pretreated population is materially positive for $6.5M-cap biotech; validates lead program justifying further development investment, though Phase 1a remains early-stage with small N and requires Phase 2 confirmation.
Price action (we called it positive)
before filing · preread $1.58 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.